๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Does interferon precipitate rejection of liver allografts?

โœ Scribed by Albert D. Min; Henry C. Bodenheimer Jr


Publisher
John Wiley and Sons
Year
1995
Tongue
English
Weight
396 KB
Volume
22
Category
Article
ISSN
0270-9139

No coin nor oath required. For personal study only.


๐Ÿ“œ SIMILAR VOLUMES


Electron microscopy of rejected human li
โœ Robert H. Fennell Jr.; John M. Vierling ๐Ÿ“‚ Article ๐Ÿ“… 1985 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 659 KB

HEPATOLOGY Copvright (c 198.5 by the American Association lor the Stud! ~J I l h e r Di.sea.sea L'ol. 5, NO. 6. pp. 1083-1087, 1%5 Printedin U.S.A.

Incidence and severity of acute allograf
โœ Jain, Ashokkumar ;Demetris, Anthony J. ;Manez, Rafael ;Tsamanadas, Athanassisos ๐Ÿ“‚ Article ๐Ÿ“… 1998 ๐Ÿ› Wiley (John Wiley & Sons) ๐ŸŒ English โš– 195 KB ๐Ÿ‘ 1 views

Interferon alfa-2b (IFN-alpha) therapy has been shown to be effective in the treatment of viral hepatitis B (HBV) or viral hepatitis C (HCV) in patients who did not undergo transplantation. However, in allograft recipients, treatment with IFN-alpha often leads to allograft rejection. The aim of the

Effects of interferon treatment on liver
โœ R. Todd Stravitz; Mitchell L. Shiffman; Arun J. Sanyal; Velimir A. Luketic; Rich ๐Ÿ“‚ Article ๐Ÿ“… 2004 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 938 KB

Recurrent hepatitis C after liver transplantation remains a significant cause of graft loss and retransplantation. Although treatment of recurrent hepatitis C with interferon-based regimens has become widely accepted as safe and can lead to sustained virologic clearance of hepatitis C virus (HCV) RN

HLA compatibility and different features
โœ G. Gubernatis; J. Kemnitz; G. Tusch; R. Pichlmayr ๐Ÿ“‚ Article ๐Ÿ“… 1988 ๐Ÿ› Springer ๐ŸŒ English โš– 571 KB

The influence of human leukocyte antigen (HLA) on acute liver allograft rejection was investigated in 48 adult patients. The diagnosis of rejection was always based on the full triad of histological findings, clinical signs, and the required antirejection treatment. Sixty-two percent of the patients